leupeptins and Wallerian-Degeneration

The ubiquitin-proteasome system (UPS), lysosomes, and autophagy are essential protein degradation systems for the regulation of a variety of cellular physiological events including the cellular response to injury. It has recently been reported that the UPS and autophagy mediate the axonal degeneration caused by traumatic insults and the retrieval of nerve growth factors. In the peripheral nerves, axonal degeneration after injury is accompanied by myelin degradation, which is tightly related to the reactive changes of Schwann cells called dedifferentiation. In this study, we examined the role of the UPS, lysosomal proteases, and autophagy in the early phase of Wallerian degeneration of injured peripheral nerves. We found that nerve injury induced an increase in the ubiquitin conjugation and lysosomal-associated membrane protein-1 expression within 1 day without any biochemical evidence for autophagy activation. Using an ex vivo explant culture of the sciatic nerve, we observed that inhibiting proteasomes or lysosomal serine proteases prevented myelin degradation, whereas this was not observed when inhibiting autophagy. Interestingly, proteasome inhibition, but not leupeptin, prevented Schwann cells from inducing dedifferentiation markers such as p75 nerve growth factor receptor and glial fibrillary acidic protein in vitro and in vivo. In addition, proteasome inhibitors induced cell cycle arrest and cellular process formation in cultured Schwann cells. Taken together, these findings indicate that the UPS plays a role in the phenotype changes of Schwann cells in response to nerve injury.

Topics: Animals; Autophagy; Axotomy; Blotting, Western; Cell Cycle; Cell Dedifferentiation; Cell Proliferation; Cells, Cultured; Cysteine Proteinase Inhibitors; Fluorescent Antibody Technique; Image Processing, Computer-Assisted; Leupeptins; Lysosomal-Associated Membrane Protein 1; Lysosomes; Mice; Nerve Fibers, Myelinated; Proteasome Endopeptidase Complex; Schwann Cells; Sciatic Nerve; Ubiquitination; Wallerian Degeneration

Treatment of transected distal axons of rat sympathetic neurons in compartmented cultures with MG132 (5 microM) and other inhibitors of proteasome activity, preserved axonal mitochondrial function, assessed by Mitotracker-Orange and MTT staining, for at least 24 h. MG132 similarly protected axons from undergoing branch elimination (pruning) in response to local NGF deprivation. Axons protected by MG132 displayed persistent phosphorylation of Erk1/2, and pharmacological inhibition of MEK activity with U0126 (50 microM) restored rapid axonal degeneration. Therefore, the proteasome does not appear to be necessary as a general effector of protein degradation during axonal degeneration. Rather, the proteasome functions in the regulation of signaling pathways that control axonal survival and degeneration. Specifically, the down-regulation of the MEK/Erk pathway by the proteasome plays roles in Wallerian degeneration of severed axons and axonal pruning in response to local NGF deprivation. Identification of the pathways that regulate axonal survival and degeneration will provide possible target sites for pharmacological treatments of neurodegenerative diseases and traumatic injury.

Topics: Animals; Animals, Newborn; Axons; Butadienes; Cell Survival; Cells, Cultured; Cysteine Proteinase Inhibitors; Down-Regulation; Enzyme Inhibitors; Leupeptins; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Nerve Growth Factor; Nerve Regeneration; Nitriles; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Rats; Rats, Sprague-Dawley; Signal Transduction; Superior Cervical Ganglion; Sympathetic Nervous System; Wallerian Degeneration

Local axon degeneration is a common pathological feature of many neurodegenerative diseases and peripheral neuropathies. While it is believed to operate with an apoptosis-independent molecular program, the underlying molecular mechanisms are largely unknown. In this study, we used the degeneration of transected axons, termed "Wallerian degeneration," as a model to examine the possible involvement of the ubiquitin proteasome system (UPS). Inhibiting UPS activity by both pharmacological and genetic means profoundly delays axon degeneration both in vitro and in vivo. In addition, we found that the fragmentation of microtubules is the earliest detectable change in axons undergoing Wallerian degeneration, which among other degenerative events, can be delayed by proteasome inhibitors. Interestingly, similar to transected axons, degeneration of axons from nerve growth factor (NGF)-deprived sympathetic neurons could also be suppressed by proteasome inhibitors. Our findings suggest a possibility that inhibiting UPS activity may serve to retard axon degeneration in pathological conditions.

Topics: Amino Acids; Animals; Animals, Newborn; Axons; Benzimidazoles; Blotting, Western; Calpain; Cells, Cultured; Chelating Agents; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Cytoskeleton; Disease Models, Animal; Drug Interactions; Egtazic Acid; Endopeptidases; Ganglia, Sympathetic; Immunohistochemistry; Leupeptins; Microtubules; Multienzyme Complexes; Nerve Growth Factor; Optic Nerve; Optic Nerve Injuries; Peptide Fragments; Proteasome Endopeptidase Complex; Rats; Time Factors; Tubulin; Ubiquitin; Wallerian Degeneration

Peripheral nerve injury results in a series of events culminating in degradation of the axonal cytoskeleton (Wallerian degeneration). In the time period between axotomy and cytoskeletal degradation (24-48 h in rodents), there is calcium entry and activation of calpains within the axon. The precise timing of these events during this period is unknown. In the present study, antibodies were generated to three distinct peptide epitopes of m-calpain, and a fusion protein antibody was generated to the intrinsic calpain inhibitor calpastatin. These antibodies were used to measure changes in these proteins in mouse sciatic nerves during Wallerian degeneration. In sciatic nerve homogenates and cultured dorsal root ganglion (DRG) neurites, m-calpain protein was significantly reduced in transected nerves very early after nerve injury, long before axonal degeneration occurred. Levels of m-calpain protein remained low as compared to control nerves for the remainder of the 72-h time course. No changes in calpastatin protein were evident. Systemic treatment of animals with the protease inhibitor leupeptin partially prevented the rapid loss of calpain protein. Removal of calcium in DRG cultures had the same effect. These data indicate that m-calpain protein is lost very early after axonal injury, and likely reflect activation and degradation of this protein long before the cytoskeleton is degraded. Calpain activation may be an early event in a proteolytic cascade that is initiated by axonal injury and culminates with axonal degeneration.

Topics: Animals; Axons; Calcium Signaling; Calcium-Binding Proteins; Calpain; Cell Membrane; Cytoskeleton; Down-Regulation; Leupeptins; Male; Mice; Mice, Inbred C57BL; Peptide Hydrolases; Peripheral Nerves; Peripheral Nervous System Diseases; Protease Inhibitors; Rabbits; Signal Transduction; Time Factors; Tubulin; Wallerian Degeneration

Biopsy specimens of human and monkey peripheral nerves, when incubated in calcium containing media, showed a loss of neurofilaments and microtubules with replacement by granular debris. Cytoskeletal structures remained intact when incubated in calcium-free media. Disruption of neurofilaments and microtubules in calcium containing media was inhibited by the thiol protease inhibitor, leupeptin. Similar incubations of excised Pacinian corpuscles revealed evidence of early terminal axon degeneration in the presence of calcium. These data substantiate the hypothesis that neural cytoskeletal degradation in primates and in man is calcium-mediated.

Topics: Animals; Calcium; Calpain; Cebus; Culture Media; Cytoskeleton; Humans; Intermediate Filaments; Leupeptins; Microtubules; Nerve Degeneration; Peripheral Nerves; Wallerian Degeneration

Investigations were undertaken on the regeneration of transected rat sciatic nerves. The ability of the protease inhibitor leupeptin to inhibit wallerian degeneration and muscle atrophy was evaluated. After transection of a sciatic nerve and immediate neurorrhaphy, animals were treated with leupeptin for a period of 1 week to 6 months. Our results indicate a significant increase in the numbers of myelinated and unmyelinated neurofibers in the distal segment of treated nerves. Peroxidase tracer, injected intramuscularly, was transported by retrograde axonal flow and was observed to label increased numbers of treated axons both distal and proximal to the repair site. This finding suggests that treated neurofibers are functionally viable. Evaluation of muscle showed that secondary muscular atrophy is also significantly inhibited by leupeptin.

Topics: Animals; Axons; Evaluation Studies as Topic; Leupeptins; Microscopy, Electron; Muscles; Muscular Atrophy; Nerve Degeneration; Nerve Fibers; Nerve Regeneration; Oligopeptides; Rats; Rats, Inbred Strains; Sciatic Nerve; Wallerian Degeneration